Zacks Investment Research upgraded shares of Opko Health (NASDAQ:OPK) from a sell rating to a hold rating in a report released on Tuesday.
According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
Other equities analysts have also issued reports about the company. Cantor Fitzgerald set a $20.00 price objective on Opko Health and gave the stock a buy rating in a report on Wednesday, October 25th. Ladenburg Thalmann Financial Services reissued a buy rating and issued a $16.00 price objective on shares of Opko Health in a report on Monday, September 25th. BidaskClub upgraded Opko Health from a sell rating to a hold rating in a research report on Saturday, September 23rd. Finally, J P Morgan Chase & Co downgraded Opko Health from an overweight rating to a neutral rating and cut their target price for the stock from $12.00 to $7.00 in a research report on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $13.97.
Opko Health (NASDAQ:OPK) opened at $5.10 on Tuesday. Opko Health has a fifty-two week low of $4.50 and a fifty-two week high of $12.15. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01.
Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The business had revenue of $263.50 million during the quarter, compared to the consensus estimate of $319.43 million. During the same period last year, the company earned ($0.03) earnings per share. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. equities analysts predict that Opko Health will post -0.27 earnings per share for the current fiscal year.
In related news, major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was bought at an average price of $3.05 per share, for a total transaction of $2,000,000.90. Following the transaction, the insider now owns 6,678,752 shares of the company’s stock, valued at $20,370,193.60. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 80,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were bought at an average price of $6.01 per share, with a total value of $480,800.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $18,444,395.51. The disclosure for this purchase can be found here. Insiders acquired 1,052,238 shares of company stock valued at $4,374,796 over the last 90 days. 40.19% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the company. Public Employees Retirement Association of Colorado lifted its holdings in shares of Opko Health by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 73,417 shares of the biotechnology company’s stock valued at $483,000 after purchasing an additional 216 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in shares of Opko Health by 0.8% in the second quarter. Pinnacle Associates Ltd. now owns 50,000 shares of the biotechnology company’s stock valued at $329,000 after purchasing an additional 397 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Opko Health by 1.7% in the second quarter. Ameriprise Financial Inc. now owns 53,788 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 896 shares in the last quarter. Prudential Financial Inc. lifted its holdings in shares of Opko Health by 6.1% in the second quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 1,400 shares in the last quarter. Finally, BB&T Securities LLC lifted its holdings in shares of Opko Health by 7.6% in the second quarter. BB&T Securities LLC now owns 20,600 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 1,460 shares in the last quarter. Institutional investors own 22.91% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Opko Health (OPK) Upgraded to “Hold” by Zacks Investment Research” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2017/12/13/opko-health-opk-upgraded-to-hold-by-zacks-investment-research.html.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.